Who Paid My Doc
Anthony Scialla
Surgery West Haven, CT Medical Doctor
NPI 1982680476 CMS profile 505168
Care Lane, Haven Health Center Of Soundview, West Haven, CT 06516
General payments
$91
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Anthony Scialla of West Haven, CT is reported in the CMS Open Payments database as having received $91 across 4 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 12th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $58 | 2 | |
| 2020 | General | $18 | 1 | |
| 2019 | General | $15 | 1 |
Beside peers
- Anthony Scialla
- Surgery median
- Middle half of Surgery
- National median
In program year 2025, general payments to Anthony Scialla were reported at $0. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.
Show as a table
| Year | Anthony Scialla | Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $15 | $253 | $82–$1,521 | $163 |
| 2020 | $18 | $131 | $40–$706 | $114 |
| 2021 | $0 | $168 | $50–$904 | $132 |
| 2022 | $58 | $224 | $76–$1,218 | $149 |
| 2023 | $0 | $253 | $82–$1,255 | $160 |
| 2024 | $0 | $279 | $90–$1,381 | $164 |
| 2025 | $0 | $280 | $91–$1,259 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 36 drugsPart D claims
1,103
Drug cost
$60,462
Branded share of claims
30.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 117 | $25,516 | |
| Jardiance Empagliflozin | Brand | 23 | $6,988 | |
| Entresto Sacubitril/Valsartan | Brand | 21 | $3,799 | |
| Tradjenta Linagliptin | Brand | 13 | $3,411 | |
| Memantine Hcl | Generic | 41 | $3,075 | |
| Autoshield Duo Pen Needle Pen Needle,dual Safety,diabetc | Brand | 26 | $2,655 | |
| Valacyclovir Valacyclovir Hcl | Brand | 12 | $1,324 | |
| Atorvastatin Calcium | Generic | 95 | $1,083 | |
| Trazodone Hcl | Generic | 82 | $1,039 | |
| Metoprolol Tartrate | Generic | 84 | $865 |
The 10 drugs with the highest cost, of 36 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgery in Connecticut
Related records
Surgery in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.